CA2671302A1 - Genes et voies regules par miarn comme cibles d'intervention therapeutique - Google Patents

Genes et voies regules par miarn comme cibles d'intervention therapeutique Download PDF

Info

Publication number
CA2671302A1
CA2671302A1 CA002671302A CA2671302A CA2671302A1 CA 2671302 A1 CA2671302 A1 CA 2671302A1 CA 002671302 A CA002671302 A CA 002671302A CA 2671302 A CA2671302 A CA 2671302A CA 2671302 A1 CA2671302 A1 CA 2671302A1
Authority
CA
Canada
Prior art keywords
nucleic acid
cell
mir
mirna
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002671302A
Other languages
English (en)
Inventor
Mike Byrom
Charles D. Johnson
David Brown
Andreas G. Bader
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Asuragen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2671302A1 publication Critical patent/CA2671302A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/111Antisense spanning the whole gene, or a large part of it
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002671302A 2006-12-08 2007-12-10 Genes et voies regules par miarn comme cibles d'intervention therapeutique Abandoned CA2671302A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86929506P 2006-12-08 2006-12-08
US60/869,295 2006-12-08
US88275806P 2006-12-29 2006-12-29
US60/882,758 2006-12-29
PCT/US2007/087038 WO2008073923A2 (fr) 2006-12-08 2007-12-10 Gènes et voies régulés par miarn comme cibles d'intervention thérapeutique

Publications (1)

Publication Number Publication Date
CA2671302A1 true CA2671302A1 (fr) 2008-06-19

Family

ID=39512449

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002671302A Abandoned CA2671302A1 (fr) 2006-12-08 2007-12-10 Genes et voies regules par miarn comme cibles d'intervention therapeutique

Country Status (5)

Country Link
EP (2) EP2102341A2 (fr)
AU (2) AU2007333110A1 (fr)
CA (1) CA2671302A1 (fr)
IL (1) IL199161A0 (fr)
WO (2) WO2008073923A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111972399A (zh) * 2020-08-06 2020-11-24 温州医科大学 维持肝细胞活性的保存液

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
MX2010005166A (es) 2007-11-09 2010-10-07 Univ Texas Micro arn de la familia mir-15 que modulan la sobrevivencia de cardiomiocitos y reparacion cardiaca.
CA2737137C (fr) 2007-12-05 2018-10-16 The Wistar Institute Of Anatomy And Biology Procede de diagnostic des cancers du poumon a l'aide de profils d'expression genetique dans des cellules mononucleaires de sang peripherique
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
JP2010094122A (ja) * 2008-06-12 2010-04-30 Keio Gijuku バイオマーカーとしてのマイクロrnaを用いた頭頸部腫瘍の診断・治療選択
US9068974B2 (en) 2008-11-08 2015-06-30 The Wistar Institute Of Anatomy And Biology Biomarkers in peripheral blood mononuclear cells for diagnosing or detecting lung cancers
KR20120118002A (ko) 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 rgm a 단백질에 대한 모노클로날 항체
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
EP3369746A1 (fr) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition et procédé pour le diagnostic et le traitement de maladies associées à la dégénérescence des neurites
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
WO2017005773A1 (fr) * 2015-07-07 2017-01-12 Universite de Bordeaux Utilisation de micro-arn ciblant la bêta-caténine pour le traitement du cancer du foie
US11692226B2 (en) 2017-07-31 2023-07-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Genotyping of SNPs to stratify cancer risk
CN111971297A (zh) * 2018-05-16 2020-11-20 韩国亿诺生物有限公司 包含lrit2抑制剂作为活性成分用于预防或治疗癌症的药物组合物
EP4684016A2 (fr) * 2023-03-20 2026-01-28 The Regents of the University of California Méthodes et matériels pour traitement du cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4939055B2 (ja) * 2002-11-13 2012-05-23 トマス ジェファソン ユニバーシティ 癌の診断および治療のための組成物および方法
CA2621441C (fr) * 2005-09-12 2014-05-20 The Ohio State University Research Foundation Compositions et methodes pour le diagnostic et le traitement de cancers associes au gene bcl2

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111972399A (zh) * 2020-08-06 2020-11-24 温州医科大学 维持肝细胞活性的保存液
CN111972399B (zh) * 2020-08-06 2021-11-30 温州医科大学 维持肝细胞活性的保存液

Also Published As

Publication number Publication date
WO2008085797A3 (fr) 2008-10-09
IL199161A0 (en) 2010-03-28
EP2102342A2 (fr) 2009-09-23
WO2008085797A8 (fr) 2009-07-16
AU2007333110A1 (en) 2008-06-19
AU2007342068A1 (en) 2008-07-17
WO2008073923A3 (fr) 2008-12-11
EP2102341A2 (fr) 2009-09-23
WO2008085797A2 (fr) 2008-07-17
WO2008073923A2 (fr) 2008-06-19

Similar Documents

Publication Publication Date Title
US20090175827A1 (en) miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
AU2007333110A1 (en) miRNA regulated genes and pathways as targets for therapeutic intervention
CN101627121A (zh) 作为治疗干预的靶标的miRNA调控基因和路径
US20090232893A1 (en) miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090163434A1 (en) miR-20 Regulated Genes and Pathways as Targets for Therapeutic Intervention
US20090227533A1 (en) miR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention
US20090192102A1 (en) miR-21 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090163435A1 (en) miR-200 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US8071562B2 (en) MiR-124 regulated genes and pathways as targets for therapeutic intervention
US20090131356A1 (en) miR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292-3P REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
EP2104737B1 (fr) Fonctions et cibles de microarn let-7
US20090192114A1 (en) miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
US20100305188A1 (en) Nucleic acid capable of regulating the proliferation of cell
Cai et al. The imprinted H19 noncoding RNA is a primary microRNA precursor
CA2671296A1 (fr) Genes et voies regules par mir-126 comme cibles d'intervention therapeutique
AU2007299873A1 (en) miR-143 regulated genes and pathways as targets for therapeutic intervention
Mo MicroRNA-21 Targets PDCD4 Expression in Retinoblastoma

Legal Events

Date Code Title Description
FZDE Discontinued